AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 292 min read$INDV

Indivior Reports Third Quarter 2026 Financial Results

Indivior Pharmaceuticals, Inc. (INDV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Indivior Reports Third Quarter 2026 Financial Results • Q3’26 Total Net Revenue of $356 Million, Up 13% YoY • Record Quarterly Total SUBLOCADE ® Net Revenue of $267 Million in Q3’26, Up 22% YoY • Record Quarterly Net Income of $137 Million and Record Non-GAAP Net Inc

Original reporting
SEC EDGAR 8-K
Published Oct 29, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 11:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$INDV
Bullish
high confidence
Mentioned
$INDV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$INDVBullishHigh
01

Why it matters

Earnings beat and merger confirmation provide a clear short‑term catalyst, likely driving the stock higher.

02

Market read

The report delivers fresh financial data and a pending merger, both of which are material for traders.

03

What to watch

Potential regulatory scrutiny of the merger and execution risk of combining operations.

Relevance 7/10Novelty 9/10Timing: today

Background

Indivior filed a Form 8‑K reporting its Q3 2026 results and merger status with Supernus.

Company-level read

Ticker impact

$INDVBullishHigh confidence
Context

Indivior reported record Q3 2026 revenue, net income and adjusted EBITDA, and confirmed the pending merger with Supernus.

Expected impact

upward pressure as investors price in earnings beat and merger completion.

Evidence & confidence

Revenue and earnings topped prior year by double‑digits, margins expanded, and the merger is set to close soon, providing a clear catalyst.

Market effects

Sector

Highlights strength in the CNS‑focused biotech sector and may lift peers.

Regional

Positive for US biotech listings.

Global

Merger creates a larger CNS player with potential global market share gains.

Counterpoint

What could challenge this read

If the merger integration risks materialize, the stock could face downside despite earnings beat.

Key entities

  • company
    Indivior Pharmaceuticals, Inc.

    Issuer reporting earnings and merger.

  • company
    Supernus Pharmaceuticals, Inc.

    Merger partner.

Read at source← All news

Related articles

OCT 30
$SUPNMed

Supernus Pharmaceuticals Inc (SUPN) Q3 2026 Earnings Call Highlights: Record Revenue

Supernus Pharmaceuticals (SUPN) reported Q3 2026 earnings, highlighting record revenue and raised guidance. CEO Jack Khattar discussed improvements in ONAPCO's form-to-shipment process, strong performance of Zerzuve, and positive trends for Calvary. The company expects to close its merger with Indivior on November 2, aiming for $125 million in annual cost synergies. SPN-817's Phase 2 readout is anticipated in 2028.

finance.yahoo.com2 min
SEP 25
$INDVMed

Indivior ends PAM drug collab with Addex ahead of Supernus merger

Indivior Pharmaceuticals ended its collaboration with Addex Therapeutics on positive allosteric modulators (PAMs) ahead of its merger with Supernus. Indivior returned all PAM assets to Addex, which plans to explore strategic options for advancing its GABAB receptor portfolio. Indivior had previously discontinued another collaboration in April. The merger with Supernus is expected to create a new CNS-focused biopharma.

fiercebiotech.com2 min